SCHEMBL5665368

SCHEMBL5665368

O=S(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.60
TAS1R1 Q7RTX1 2/20 0.60
ADORA1 P30542 3/20 0.57
RXFP1 Q9HBX9 1/20 0.55
TRPM2 O94759 2/20 0.55
DNPH1 O43598 1/20 0.55
PRKAB2 O43741 1/20 0.55
LDHA P00338 1/20 0.55
ADRB2 P07550 1/20 0.55
FBP1 P09467 1/20 0.55
SRC P12931 1/20 0.55
P2RY2 P41231 1/20 0.55
P2RY1 P47900 1/20 0.55
PRKAG1 P54619 1/20 0.55
PRKAA2 P54646 1/20 0.55
PDE4D Q08499 1/20 0.55
KCNH2 Q12809 1/20 0.55
PRKAA1 Q13131 1/20 0.55
PDE3A Q14432 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5663970 0.90 ADORA1 (0.69) TAS1R3TAS1R1ADORA1RXFP1TRPM2
SCHEMBL1066377 0.88 TAS1R3 (0.75) TAS1R3TAS1R1ADORA1RXFP1TRPM2
SCHEMBL8954219 0.88 TAS1R3 (0.75) TAS1R3TAS1R1ADORA1RXFP1TRPM2
SCHEMBL29754360 0.88 TAS1R3 (0.75) TAS1R3TAS1R1ADORA1RXFP1TRPM2
SCHEMBL11426071 0.87 CA1 (0.58) TAS1R3TAS1R1ADORA1RXFP1SARS1
Inosine SCHEMBL5896867 0.85 SLC29A1 (0.67) ADORA1RXFP1SMN1; SMN2ADORA3ADORA2A
Inosine SCHEMBL5896892 0.85 SLC29A1 (0.67) ADORA1RXFP1SMN1; SMN2ADORA3ADORA2A
SCHEMBL28672421 0.85 P2RY1 (0.57) TAS1R3TAS1R1ADORA1TRPM2DNPH1
SCHEMBL3505762 0.85 P2RY1 (0.58) TAS1R3TAS1R1ADORA1TRPM2DNPH1
SCHEMBL317726 0.84 P2RY1 (0.57) TAS1R3TAS1R1ADORA1TRPM2DNPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010053763-A1 Method and composition for modulating an immune response INOTEK PHARMACEUTICALS CORPORATION 2001-12-20 US claimed
US-4242505-A S-Adenosyl-L-methionine compositions and production thereof YAMASA SHOYU KABUSHIKI KAISHA (JP) 1980-12-30 US claimed
JP-54154774-A None JP disclosed
JP-54109998-A None JP disclosed
EP-1383505-A4 INOSINE COMPOUNDS AND THEIR USE FOR TREATING OR PREVENTING AN INFLAMATION OR A REPERFUSION DISEASE INOTEK PHARMACEUTICALS CORP (US) 2006-08-09 EP disclosed
US-7049301-B2 Quercetin derivatives and their medical usages ACADEMY OF MILITARY MEDICAL SCIENCES INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY (CN) 2006-05-23 US disclosed
US-6958324-B2 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease INOTEK PHARMACEUTICALS CORPORATION (US) 2005-10-25 US disclosed
US-20050203052-A1 Inosine compounds and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION 2005-09-15 US disclosed
US-20050026078-A1 Resist compositions including thermal crosslinking agents CHOI SANG-JUN (KR) 2005-02-03 US disclosed
US-20050014715-A1 Inosine compounds and their use for treating or preventing an inflammation or reperfusion disease SALZMAN ANDREW L (US) 2005-01-20 US disclosed
US-6803176-B2 FORMING PHOTORESIST BY PHOTOLITHOGRAPHY SAMSUNG ELECTRONICS CO., LTD. (KR) 2004-10-12 US disclosed
US-20040132671-A1 Quercetin derivatives and their medical usages ACADEMY OF MILITARY MEDICAL SCIENCES INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY 2004-07-08 US disclosed
EP-1383505-A2 INOSINE COMPOUNDS AND THEIR USE FOR TREATING OR PREVENTING AN INFLAMATION OR A REPERFUSION DISEASE Inotek Pharmaceuticals Corporation (US) 2004-01-28 EP disclosed
US-20030054292-A1 Methods for forming line patterns in semiconductor substrates CHOI SANG-JUN (KR) 2003-03-20 US disclosed
US-20030040502-A1 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease INOTEK PHARMACEUTICALS CORPORATION 2003-02-27 US disclosed
US-6485895-B1 Methods for forming line patterns in semiconductor substrates SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-11-26 US disclosed
WO-2002076400-A2 INOSINE COMPOUNDS AND THEIR USE FOR TREATING OR PREVENTING AN INFLAMATION OR A REPERFUSION DISEASE INOTEK PHARMACEUTICALS CORPORATION (US) 2002-10-03 WO disclosed
US-20010053763-A1 Method and composition for modulating an immune response INOTEK PHARMACEUTICALS CORPORATION 2001-12-20 US disclosed
US-4242505-A S-Adenosyl-L-methionine compositions and production thereof YAMASA SHOYU KABUSHIKI KAISHA (JP) 1980-12-30 US disclosed
JP-S54109998-A COMPOSITION CONTAINING S-ADENOSYL-L-METHIONINE AND ITS PREPARATION YAMASA SHOYU CO LTD 1979-08-29 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132671-A1 Quercetin derivatives and their medical usages HTR1A, HTR2A, HTR5A TAS1R3 952/4885TAS1R1 872/4885ADORA1 78/4885
US-20050203052-A1 Inosine compounds and methods of use thereof NOS2, NOS1, ARG2 TAS1R3 4112/4885TAS1R1 3804/4885ADORA1 185/4885
US-20010053763-A1 Method and composition for modulating an immune response SLC11A2, ATP1A2, MSR1 TAS1R3 3678/4885TAS1R1 3419/4885ADORA1 172/4885
US-20030040502-A1 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease NOS2, NOS1, ARG2 TAS1R3 2891/4885TAS1R1 2332/4885ADORA1 159/4885
US-20050014715-A1 Inosine compounds and their use for treating or preventing an inflammation or reperfusion disease NOS2, NOS1, NOS3 TAS1R3 3627/4885TAS1R1 3378/4885ADORA1 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.